Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Search Results

Showing 1 - 10 of 29 results for "Pfizer"

Big spend on cost of living, defence

ELIZABETH MCARTHUR  |  TUESDAY, 29 MAR 2022
... Budget by way of a new focus on sovereign manufacturing capability. New federal funding will see mRNA vaccines - like the Pfizer and Moderna vaccines - manufactured in Victoria. Environmental spending still contentious While the LNP government has been ...

How to invest in China: Capital Group

JAMIE WILLIAMSON  |  WEDNESDAY, 12 JAN 2022
... further efforts to match global standards. Examples of global firms partnering with Chinese businesses include AstraZeneca, Pfizer and Novartis, while Chinese firms such as BeiGene and Legend Biotech have also found multinational partners. "Authorities ...

Chief economist update: The vaccine has landed

BENJAMIN ONG  |  MONDAY, 22 FEB 2021
... the rollout, with more than 500,000 aged and disability care residents and staff" for a total of 678,000. About 60,000 Pfizer/BioNTech COVID-19 vaccine doses are expected to be administered to priority groups by the end of the first week." Phase 1B will ...

Chief economist update: Japan's five minutes of sunshine

BENJAMIN ONG  |  WEDNESDAY, 9 DEC 2020
... the coronavirus vaccine but at this point supply remains limited. According to Factset: "Washington Post reported that Pfizer told the Trump administration it cannot provide substantial additional doses of its vaccine until late June or July... FT also ...

Chief economist update: The virus, the vaccine and Trump

BENJAMIN ONG  |  MONDAY, 23 NOV 2020
... to remain stable at standard refrigerator temperatures of 2-8 degrees centigrade for up to 30 days. This is better than Pfizer and BioNTech's candidate which reportedly is 90% effective and needs to be stored at around minus 70 degrees centigrade. ...

Chief economist update: A vaccine and a better vaccine

BENJAMIN ONG  |  TUESDAY, 17 NOV 2020
... days. This comes in the wake of some of the logistics/distribution concerns (WSJ) surrounding the vaccine candidate from Pfizer (PFE-US ) and BioNTech (BNTX-US ). While the recently announced efficacy rate was also over 90%, helping to unleash a bullish ...

Chief economist update: Oil could slip on fresh lockdowns

BENJAMIN ONG  |  THURSDAY, 12 NOV 2020
... US$41.36 per barrel; Brent oil to US$43.61 - following reports of encouraging COVID-19 vaccine test results developed by Pfizer and BioNTech. The easing of US presidential election uncertainty, topped by Joe Biden trumping Donald Trump has also helped ...

Chief economist update: Letter V going viral in Australia

BENJAMIN ONG  |  WEDNESDAY, 11 NOV 2020
... that soon, the coronavirus pandemic too, shall pass following encouraging test results for a COVID-19 vaccine developed by Pfizer and BioNTech.

Chief economist update: V for vaccine

BENJAMIN ONG  |  TUESDAY, 10 NOV 2020
It's beginning to look a lot like Christmas. Encouraging test results for a COVID-19 vaccine developed by Pfizer and BioNTech sent world equity markets from New York to Rio and ol' London town on the up and up and up. Pfizer and BioNTech are ...

US bonds present ESG problem

ELIZABETH MCARTHUR  |  MONDAY, 15 JUL 2019
... companies," Ground said. "Some of the worst behaviour is a bit under the radar." She explained that Schroders has a holding in Pfizer and engages with the company on many levels - naming drug pricing, antibiotics, chief executive pay and capital allocation ...
PAGE:
1
PREVIOUS
NEXT